Orphan Drug Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Orphan Drug stocks.

Orphan Drug Stocks Recent News

Date Stock Title
Nov 22 CYTK Cytokinetics price target raised to $103 from $99 at Mizuho
Nov 21 CYTK Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?
Nov 21 BIVI BioVie files to sell 7.71M shares of common stock for holders
Nov 21 IONS Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?
Nov 21 GMAB Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?
Nov 20 CYTK Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Nov 20 BIVI BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
Nov 20 IONS Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
Nov 19 FOLD HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
Nov 19 CYTK Cytokinetics and Bayer partner to develop for aficamten in Japan
Nov 19 CYTK Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
Nov 19 CYTK Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan
Nov 19 CYTK Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Nov 19 CYTK Bayer acquires rights to Cytokinetics' heart drug in Japan
Nov 19 CYTK Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Nov 18 PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver MeetingĀ® 2024
Nov 18 CRDL Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Nov 18 IONS Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Orphan Drug

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy in many countries and has yielded medical breakthroughs that might not otherwise have been achieved, due to the economics of drug research and development.In the U.S. and the EU, it is easier to gain marketing approval for an orphan drug. There may be other financial incentives, such as an extended period of exclusivity, during which the producer has sole rights to market the drug. All are intended to encourage development of drugs which would otherwise lack sufficient profit motive to attract corporate research budgets and personnel.

Browse All Tags